Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: Ocrelizumab

Positive 4-year efficacy and safety data of ocrelizumab in early MS

Trial
Phase 3, ENSEMBLE
Conference
AAN 2023

26 June, 2023 20:36

Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes

Presented By
Dr Nikos Evangelou, Nottingham University Hospital, UK
Conference
ECTRIMS 2022

20 December, 2022 11:46

Pregnancy and infant outcomes in women receiving ocrelizumab

Presented By
Prof. Celia Oreja-Guevara, University Hospital San Carlos, Spain
Conference
ECTRIMS 2022

20 December, 2022 10:29

New safety data of anti-CD20 mAbs around pregnancy

Presented By
Dr Carolin Schwake, Ruhr-University Bochum, Germany
Conference
ECTRIMS 2022

20 December, 2022 10:24

Comparing real-world effectiveness of DMTs

Presented By
Prof. Marcello Moccia, University College London, UK
Conference
ECTRIMS 2022

20 December, 2022 09:05

Study fails to show non-inferiority of rituximab to ocrelizumab

Presented By
Dr Izanne Roos, University of Melbourne, Australia
Conference
ECTRIMS 2022

20 December, 2022 08:55

ECTRIMS 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ECTRIMS 2022

15 November, 2022 00:08

Charcot Award 2021: Progressive MS, a personal perspective

Presented By
Prof. Alan J. Thompson, University College London, UK
Conference
ECTRIMS 2021

9 December, 2021 15:48

Ocrelizumab shows long-term benefits in primary progressive MS

Presented By
Prof. Jerry S. Wolinsky, University of Texas Health Science Center at Houston, TX, USA
Trial
Phase 3, ORATORIO
Conference
ECTRIMS 2021

9 December, 2021 15:39

ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

Presented By
Prof. Xavier Montalban, Vall d’Hebron University Hospital, Spain
Conference
ECTRIMS 2021

9 December, 2021 14:37

Long-term suppression of MRI disease activity with ocrelizumab

Presented By
Dr Douglas Arnold, McGill University, Canada
Trial
Phase 3, OPERA I/II, ORATORIO
Conference
ECTRIMS 2021

9 December, 2021 14:30

Elezanumab did not outperform placebo in progressive and relapsing MS

Presented By
Prof. Bruce Cree, University of California, CA, USA
Trial
Phase 2, RADIUS-R, RADIUS-P
Conference
ECTRIMS 2021

9 December, 2021 14:10

MS patients at risk of hampered immune response after vaccination

Presented By
Prof. Maria Pia Sormani, University of Genoa, Italy
Conference
ECTRIMS 2021

9 December, 2021 10:49

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By
Dr Steve Simpson-Yap, University of Melbourne, Australia
Conference
ECTRIMS 2021

9 December, 2021 10:41

ECTRIMS-EAN consensus on vaccination in MS patients

Presented By
Dr Mauricio Farez, Fundacion FLENI, Argentina
Conference
ECTRIMS 2021

9 December, 2021 10:35

MS therapies influence COVID-19 severity

Conference
AAN 2021

16 June, 2021 11:42

Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?

Presented By
Dr Steve Simpson-Yap, Melbourne School of Population and Global Health, Australia
Journal
Physician’s Weekly
Conference
MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

15 April, 2021 16:27

Real-world efficacy of ocrelizumab in MS patients

Presented By
Julius Eggebrecht, Roche Pharma, Germany
Trial
Phase 4, CONFIDENCE
Conference
ECF 2020

16 December, 2020 10:24

Risk of COVID-19 not increased in MS patients

Conference
MS Virtual 2020

25 November, 2020 17:10

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference
MS Virtual 2020

25 November, 2020 17:09

Management of progressive MS with approved DMT

Presented By
Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain
Trial
ASCEND, MS-SMART
Conference
MS Virtual 2020

25 November, 2020 17:01

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference
MS Virtual

25 November, 2020 16:59

High NEDA rates after 2 years of ocrelizumab

Presented By
Prof. Patrick Vermersch, University of Lille, France
Trial
Phase 3, CASTING
Conference
EAN 2020

10 September, 2020 12:25

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By
Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA
Conference
EAN 2020

10 September, 2020 12:17

Treatment escalation over induction therapy

Presented By
Dr Emmanuelle Waubant, University of California, San Francisco, USA
Conference
ECTRIMS 2019

8 November, 2019 22:40

Sustained reduction in disability progression with ocrelizumab

Presented By
Prof. Jerry Wolinsky, University of Texas, USA
Trial
Phase 3, ORATORIO
Conference
ECTRIMS 2019

8 November, 2019 19:32

Serum immunoglobulin levels and risk of serious infections

Presented By
Prof. Tobias Derfuss, University Hospital Basel, Switzerland
Conference
ECTRIMS 2019

8 November, 2019 19:23

Sequencing of high-efficacy disease-modifying treatments in MS

Trial
OCTAVE
Conference
AAN 2019

30 July, 2019 20:12

Biotin, ocrelizumab, and ibudilast in progressive MS

Expert
Dr Andrew Goodman, University of Rochester School of Medicine and Dentistry, USA
Trial
ORATORIO, Phase 3; SPRINT-MS, Phase 2; MS-SPI, Phase 3
Conference
AAN 2019

30 July, 2019 19:15
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy